Helping You to Find Mechanistic Keys to Biomarker Discovery for Precision Oncology
View video
Clustering analysis of recently approved kinase inhibitors presented at Discovery on Target 2020 – Virtual
September 14, 2020: Hierarchical clustering of kinase inhibitors based on their IC50 [...]
NTRC launches new website: www.residencetimer.com
July 30, 2020: NTRC launches www.residencetimer.com for biochemical assays in drug discovery. [...]
PREMIUM BENEFITS OF NTRC PRECISION ONCOLOGY: Cell-Based Assays, Drug Combinations, High-Throughput Screening
Integration of cancer biology and big data analysis
Identification of patient selection markers
Side-by-side comparison with known anti-cancer agents
Discovery of targeted and novel synergistic drug combinations
Science-driven technology platforms
Short turnaround times
